bevacizumab + carboplatin + gefitinib + icotinib + pemetrexed

This is a non-proprietary, non-fixed treatment-regimen label for advanced **EGFR-mutated non-squamous non-small cell lung cancer**. It is not a single five-drug product: the cited retrospective study administered **either gefitinib or icotinib**, not both EGFR tyrosine kinase inhibitors concurrently, together with intravenous bevacizumab, pemetrexed, and carboplatin; therefore, this input represents alternative first-generation EGFR-TKI-containing regimens rather than one exact five-agent regimen. Bevacizumab neutralizes VEGF-A to inhibit tumor angiogenesis; gefitinib and icotinib reversibly inhibit EGFR kinase signaling; pemetrexed inhibits folate-dependent nucleotide-synthesis enzymes; and carboplatin produces cytotoxic DNA crosslinks. ([tandfonline.com](https://www.tandfonline.com/doi/pdf/10.1080/07853890.2023.2243967))